L. Mark Fisher

6.8k total citations
102 papers, 5.6k citations indexed

About

L. Mark Fisher is a scholar working on Molecular Biology, Molecular Medicine and Oncology. According to data from OpenAlex, L. Mark Fisher has authored 102 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Molecular Biology, 33 papers in Molecular Medicine and 24 papers in Oncology. Recurrent topics in L. Mark Fisher's work include Cancer therapeutics and mechanisms (83 papers), Antibiotic Resistance in Bacteria (33 papers) and Antibiotics Pharmacokinetics and Efficacy (23 papers). L. Mark Fisher is often cited by papers focused on Cancer therapeutics and mechanisms (83 papers), Antibiotic Resistance in Bacteria (33 papers) and Antibiotics Pharmacokinetics and Efficacy (23 papers). L. Mark Fisher collaborates with scholars based in United Kingdom, United States and France. L. Mark Fisher's co-authors include Xiao-Su Pan, Caroline A. Austin, Mark Oram, Martin Gellert, M H O'Dea, Jane E. Ambler, Alexandra Aubry, Sandhiya Patel, Reiko Kuroda and Emmanuelle Cambau and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

L. Mark Fisher

101 papers receiving 5.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L. Mark Fisher United Kingdom 41 3.9k 1.9k 1.6k 998 916 102 5.6k
Robert J. Kerns United States 29 2.6k 0.7× 1.3k 0.7× 997 0.6× 397 0.4× 565 0.6× 75 4.1k
Malcolm G. P. Page Switzerland 43 2.3k 0.6× 2.3k 1.2× 1.3k 0.8× 753 0.8× 994 1.1× 115 5.1k
Frank Schweizer Canada 39 3.0k 0.8× 2.8k 1.4× 1.7k 1.1× 1.0k 1.0× 880 1.0× 153 6.7k
Lynn L. Silver United States 36 2.5k 0.6× 1.7k 0.9× 1.0k 0.7× 450 0.5× 654 0.7× 73 5.4k
N H Georgopapadakou United States 30 1.5k 0.4× 979 0.5× 1.1k 0.7× 732 0.7× 1.1k 1.2× 86 3.8k
Cheryl A. Janson United States 43 3.1k 0.8× 488 0.3× 465 0.3× 443 0.4× 506 0.6× 67 5.1k
Terry L. Bowlin United States 38 1.9k 0.5× 562 0.3× 394 0.2× 1.1k 1.1× 843 0.9× 161 4.6k
Hiroshi Hiasa United States 31 2.6k 0.7× 696 0.4× 581 0.4× 135 0.1× 187 0.2× 72 3.4k
Courtney C. Aldrich United States 42 3.1k 0.8× 356 0.2× 1.5k 0.9× 595 0.6× 1.0k 1.1× 164 5.0k
Mikael Elofsson Sweden 36 3.0k 0.8× 585 0.3× 276 0.2× 517 0.5× 428 0.5× 132 5.3k

Countries citing papers authored by L. Mark Fisher

Since Specialization
Citations

This map shows the geographic impact of L. Mark Fisher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Mark Fisher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Mark Fisher more than expected).

Fields of papers citing papers by L. Mark Fisher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Mark Fisher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Mark Fisher. The network helps show where L. Mark Fisher may publish in the future.

Co-authorship network of co-authors of L. Mark Fisher

This figure shows the co-authorship network connecting the top 25 collaborators of L. Mark Fisher. A scholar is included among the top collaborators of L. Mark Fisher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Mark Fisher. L. Mark Fisher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Laponogov, Ivan, et al.. (2018). Trapping of the transport-segment DNA by the ATPase domains of a type II topoisomerase. Nature Communications. 9(1). 2579–2579. 22 indexed citations
2.
Laponogov, Ivan, Dennis A. Veselkov, Ryan T. Cirz, et al.. (2016). Exploring the active site of the Streptococcus pneumoniae topoisomerase IV–DNA cleavage complex with novel 7,8-bridged fluoroquinolones. Open Biology. 6(9). 160157–160157. 23 indexed citations
3.
Laponogov, Ivan, Xiao-Su Pan, Dennis A. Veselkov, et al.. (2010). Correction: Structural Basis of Gate-DNA Breakage and Resealing by Type II Topoisomerases. PLoS ONE. 5(7). 25 indexed citations
4.
Cambau, Emmanuelle, Stéphanie Matrat, Xiao-Su Pan, et al.. (2009). Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. Journal of Antimicrobial Chemotherapy. 63(3). 443–450. 72 indexed citations
5.
Sohi, Maninder K., Dennis A. Veselkov, Ivan Laponogov, et al.. (2008). The Difficult Case of Crystallization and Structure Solution for the ParC55 Breakage-Reunion Domain of Topoisomerase IV from Streptococcus pneumoniae. PLoS ONE. 3(9). e3201–e3201. 2 indexed citations
6.
Sriram, Dharmarajan, Alexandra Aubry, Perumal Yogeeswari, & L. Mark Fisher. (2006). Gatifloxacin derivatives: Synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. Bioorganic & Medicinal Chemistry Letters. 16(11). 2982–2985. 106 indexed citations
7.
Patel, Sandhiya, Elen Jazrawi, Andrew M. Creighton, Caroline A. Austin, & L. Mark Fisher. (2000). Probing the Interaction of the Cytotoxic Bisdioxopiperazine ICRF-193 with the Closed Enzyme Clamp of Human Topoisomerase IIα. Molecular Pharmacology. 58(3). 560–568. 22 indexed citations
8.
Fisher, L. Mark. (2000). High-fat diet and prostate cancer: the controversial connection.. PubMed. 20(3). 205–6, 209. 1 indexed citations
9.
Patel, Sandhiya, et al.. (2000). Mutations at Arg486 and Glu571 in Human Topoisomerase IIα Confer Resistance to Amsacrine: Relevance for Antitumor Drug Resistance in Human Cells. Molecular Pharmacology. 57(4). 784–791. 4 indexed citations
10.
11.
12.
Fisher, L. Mark, et al.. (1998). Low‐ versus high‐dose azithromycin triple therapy for Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics. 12(12). 1263–1267. 20 indexed citations
13.
Willmore, Elaine, et al.. (1996). Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIα (p170) and IIβ (p180). Molecular Pharmacology. 14 indexed citations
14.
Sun, Li, et al.. (1996). NorA plasmid resistance to fluoroquinolones: role of copy number and norA frameshift mutations. Antimicrobial Agents and Chemotherapy. 40(7). 1665–1669. 13 indexed citations
15.
Alonso, Juan C. & L. Mark Fisher. (1995). Nucleotide sequence of the recF gene cluster from Staphylococcus aureus and complementation analysis in Bacillus subtilis recF mutants. Molecular and General Genetics MGG. 246(6). 680–686. 8 indexed citations
16.
Fisher, L. Mark, Caroline A. Austin, Robert Hopewell, et al.. (1992). DNA supercoiling and relaxation by ATP-dependent DNA topoisomerases. Philosophical Transactions of the Royal Society B Biological Sciences. 336(1276). 83–91. 10 indexed citations
17.
Fasching, C E, Fred C. Tenover, Thomas G. Slama, et al.. (1991). gyrA Mutations in Ciprofloxacin-Resistant, Methicillin-Resistant Staphylococcus aureus from Indiana, Minnesota, and Tennessee. The Journal of Infectious Diseases. 164(5). 976–979. 31 indexed citations
18.
19.
Fisher, L. Mark, et al.. (1989). Ciprofloxacin and the fluoroquinolones. The American Journal of Medicine. 87(5). S2–S8. 85 indexed citations
20.
Fisher, L. Mark, et al.. (1973). Experience in the treatment of hepatic failure by intermittent liver hemoperfusions.. PubMed. 137(5). 741–52. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert J. Kerns Breakdown of academic impact, for papers by Malcolm G. P. Page Breakdown of academic impact, for papers by Frank Schweizer Breakdown of academic impact, for papers by Lynn L. Silver Breakdown of academic impact, for papers by N H Georgopapadakou Breakdown of academic impact, for papers by Cheryl A. Janson Breakdown of academic impact, for papers by Terry L. Bowlin Breakdown of academic impact, for papers by Hiroshi Hiasa Breakdown of academic impact, for papers by Courtney C. Aldrich Breakdown of academic impact, for papers by Mikael Elofsson
Rankless by CCL
2026